The Liposome Company Plans Product In-Licensing To Combat Evacet Delays
Executive Summary
The Liposome Company plans to buy or in-license a product from another company to compensate for delays in the approval of Evacet for the treatment of metastatic breast cancer, CEO Charles Baker told analysts.
You may also be interested in...
The Liposome Company Moves Past Evacet Set-Backs With Elan Merger
Elan would add a 40 rep oncology sales force to market its non-opioid analgesic ziconotide with the acquisition of The Liposome Company announced March 6.
The Liposome Company Moves Past Evacet Set-Backs With Elan Merger
Elan would add a 40 rep oncology sales force to market its non-opioid analgesic ziconotide with the acquisition of The Liposome Company announced March 6.
The Liposome Company Evacet
Additional clinical data will be needed to gain FDA approval for metastatic breast cancer based on discussions with FDA, company says Feb. 3. The company is considering foregoing the metastatic indication in favor of pursuing a lymphoma indication. The company had submitted analyses to FDA to support resubmission of the Evacet application following withdrawal of the original application (1"The Pink Sheet" Oct. 18, 1999, In Brief)
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: